Intravenous bisphosphonate therapy for osteoporosis: Where do we stand?
- Cite this article as:
- Bone, H.G. & Schurr, W. Curr Osteoporos Rep (2004) 2: 24. doi:10.1007/s11914-004-0011-5
The use of oral bisphosphonates, particularly members of the aminobisphosphonate subclass, is well established for the treatment of osteoporosis. In a number of clinical settings, intravenous administration appears to be advantageous. However, current dosing and efficacy data are limited while definitive, long-term trials with some of these agents are ongoing. In this article, we review the available information and discuss the use of these drugs on that basis.